Home  »  Business   »  Inovio Pharmaceuticals Inc. (INO) Just Got Our Att...

Inovio Pharmaceuticals Inc. (INO) Just Got Our Attention

Inovio Pharmaceuticals Inc. (NASDAQ:INO) went down by -0.97% from its latest closing price compared to the recent 1-year high of $7.77. The company’s stock price has collected -12.39% of loss in the last five trading sessions.

Is It Worth Investing in Inovio Pharmaceuticals Inc. (NASDAQ :INO) Right Now?

Plus, the 36-month beta value for INO is at 1.04. Opinions of the stock are interesting as 0 analysts out of 7 who provided ratings for Inovio Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 6 rated it as “hold,” and 0 as “sell.”

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report

Sponsored

The average price from analysts is $2.25, which is $0.2 above the current price. INO currently public float of 245.68M and currently shorts hold a 17.78% ratio of that float. Today, the average trading volume of INO was 5.83M shares.

INO’s Market Performance

INO stocks went down by -12.39% for the week, with a monthly jump of 9.04% and a quarterly performance of -17.84%, while its annual performance rate touched -70.29%. The volatility ratio for the week stands at 7.01% while the volatility levels for the past 30 days are set at 9.49% for Inovio Pharmaceuticals Inc. The simple moving average for the period of the last 20 days is -6.84% for INO stocks with a simple moving average of -14.71% for the last 200 days.

Analysts’ Opinion of INO

BofA Securities, on the other hand, stated in their research note that they expect to see INO reach a price target of $2. The rating they have provided for INO stocks is “Underperform” according to the report published on November 01st, 2022.

RBC Capital Mkts gave a rating of “Sector Perform” to INO, setting the target price at $4 in the report published on July 19th of the current year.

INO Trading at 5.90% from the 50-Day Moving Average

After a stumble in the market that brought INO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.62% of loss for the given period.

Volatility was left at 9.49%, however, over the last 30 days, the volatility rate increased by 7.01%, as shares surge +4.06% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.50% upper at present.

During the last 5 trading sessions, INO fell by -12.39%, which changed the moving average for the period of 200-days by -43.99% in comparison to the 20-day moving average, which settled at $2.20. In addition, Inovio Pharmaceuticals Inc. saw -58.92% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at INO starting from Weiner David B., who sale 11,875 shares at the price of $2.66 back on Aug 11. After this action, Weiner David B. now owns 892,625 shares of Inovio Pharmaceuticals Inc., valued at $31,588 using the latest closing price.

BENITO SIMON X, the Director of Inovio Pharmaceuticals Inc., sale 2,000 shares at $2.25 during a trade that took place back on Jul 20, which means that BENITO SIMON X is holding 75,305 shares at $4,500 based on the most recent closing price.

Stock Fundamentals for INO

Current profitability levels for the company are sitting at:

  • -17535.79 for the present operating margin
  • -166.56 for the gross margin

The net margin for Inovio Pharmaceuticals Inc. stands at -17109.87. Equity return is now at value -100.80, with -74.10 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 6.82.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]